Literature DB >> 26855969

Recruitment, Follow-Up and Characteristics of HIV Infected Adults who Use Illicit Drugs in Southern Africa.

Marianna K Baum1, Adriana Campa1, J Bryan Page2, Shenghan Lai3, Lesedi Tsalaile4, Sabrina Sales Martinez1, Patricia Burns5, O'Dale Williams1, Yinghui Li1, Erik van Widenfelt4, Herman Bussmann4, Moyo Sikhulele4, Joseph Makhema4, Myron Essex5, Richard Marlink5.   

Abstract

BACKGROUND: With one of the worst HIV prevalence rates in the world, Botswana has made great strides in addressing AIDS. Nevertheless, to fully contain the epidemic, outreach to marginalized groups, including illicit drug users, is critical.
OBJECTIVE: To conduct targeted outreach within an intervention trial to recruit HIV-infected drug users and assess HIV disease and nutritional status.
METHOD: Recruitment strategies included safeguarding confidentiality, involving ocal health-care professionals, advertising, and participation incentives. Urine toxicology, CD4 cell count, HIV viral load, blood chemistry, plasma micronutrients, dietary history, drug use and morbidity were assessed for two years.
RESULTS: Targeted outreach identified 138 HIV-infected persons who used marijuana; 18.1% had CD4 cell counts ≤ 350 cells/μL and 39.9% had low BMI. Eligible marijuana users (N=52) had significantly lower BMI (21.8 3.7 vs. 24.3 ± 5.3 kg/m2, P=0.001), higher HIV viral load (4.36 ± 0.89 vs. 4.09 ± 0.89 log10, P=0.018), and higher kilocalorie intake (1924 ± 1055 vs. 1620 ± 926 Kcalories, P=0.025) than those who did not use marijuana (N=748) with similar CD4 cell count. Marijuana users ≥ 40 years old had more opportunistic diseases (P=0.020) than non-users of the same age. Benzodiazepine use was detected among 57 participants and they had higher BMI than marijuana users (24.4 ± 6.8 vs. 21.8 ± 3.7 kg/m2, P= 0.017).
CONCLUSION: A population stigmatized by illicit drug use and HIV-infection can be brought into a clinical research setting in Africa. HIV-infected marijuana users were at a risk for higher HIV viral load, lower BMI and more comorbidities than nonusers. Outreach to this marginalized group is important for containing the HIV epidemic.

Entities:  

Keywords:  Benzodiazepines; Botswana; HIV; HIV disease progression; Marijuana; Nutritional status; Recruitment

Year:  2015        PMID: 26855969      PMCID: PMC4739794          DOI: 10.21767/2471-853x.10007

Source DB:  PubMed          Journal:  J Drug Abuse        ISSN: 2471-853X


  35 in total

Review 1.  Cannabinoid neuroimmune modulation of SIV disease.

Authors:  Patricia E Molina; Angela Amedee; Nicole J LeCapitaine; Jovanny Zabaleta; Mahesh Mohan; Peter Winsauer; Curtis Vande Stouwe
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-10       Impact factor: 4.147

Review 2.  Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives.

Authors:  L P Longo; B Johnson
Journal:  Am Fam Physician       Date:  2000-04-01       Impact factor: 3.292

3.  Trouble-free microbiologic serum and red cell folate assays.

Authors:  J M Scott; V Ghanta; V Herbert
Journal:  Am J Med Technol       Date:  1974-03

4.  Chronic Δ⁹-tetrahydrocannabinol administration may not attenuate simian immunodeficiency virus disease progression in female rhesus macaques.

Authors:  Angela M Amedee; Whitney A Nichols; Nicole J LeCapitaine; Curtis Vande Stouwe; Leslie L Birke; Nedra Lacour; Peter J Winsauer; Patricia E Molina
Journal:  AIDS Res Hum Retroviruses       Date:  2014-12       Impact factor: 2.205

5.  Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral-naive, HIV-infected adults in Botswana: a randomized clinical trial.

Authors:  Marianna K Baum; Adriana Campa; Shenghan Lai; Sabrina Sales Martinez; Lesedi Tsalaile; Patricia Burns; Mansour Farahani; Yinghui Li; Erik van Widenfelt; John Bryan Page; Hermann Bussmann; Wafaie W Fawzi; Sikhulele Moyo; Joseph Makhema; Ibou Thior; Myron Essex; Richard Marlink
Journal:  JAMA       Date:  2013-11-27       Impact factor: 56.272

6.  Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial.

Authors:  Donald I Abrams; Joan F Hilton; Roslyn J Leiser; Starley B Shade; Tarek A Elbeik; Francesca T Aweeka; Neal L Benowitz; Barry M Bredt; Bradley Kosel; Judith A Aberg; Steven G Deeks; Thomas F Mitchell; Kathleen Mulligan; Peter Bacchetti; Joseph M McCune; Morris Schambelan
Journal:  Ann Intern Med       Date:  2003-08-19       Impact factor: 25.391

7.  Multiple discriminations experienced by people living with HIV in France: results from the ANRS-Vespa2 study.

Authors:  Elise Marsicano; Rosemary Dray-Spira; France Lert; Cindy Aubrière; Bruno Spire; Christine Hamelin
Journal:  AIDS Care       Date:  2014-04-16

8.  HIV transmission risk behaviours among HIV seropositive sexually transmitted infection clinic patients in Cape Town, South Africa.

Authors:  Seth C Kalichman; Leickness C Simbayi; Demetria Cain
Journal:  Eur J Public Health       Date:  2009-09-02       Impact factor: 3.367

9.  An exploratory survey measuring stigma and discrimination experienced by people living with HIV/AIDS in South Africa: the People Living with HIV Stigma Index.

Authors:  Monika Ml Dos Santos; Pieter Kruger; Shaun E Mellors; Gustaaf Wolvaardt; Elna van der Ryst
Journal:  BMC Public Health       Date:  2014-01-27       Impact factor: 3.295

10.  Using health surveillance systems data to assess the impact of AIDS and antiretroviral treatment on adult morbidity and mortality in Botswana.

Authors:  Rand Stoneburner; Eline Korenromp; Mark Lazenby; Jean-Michel Tassie; Judith Letebele; Diemo Motlapele; Reuben Granich; Ties Boerma; Daniel Low-Beer
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

View more
  1 in total

1.  Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy.

Authors:  Wei Jiang; Zhenwu Luo; Lisa Martin; Zhuang Wan; Pingfu Fu; Amanda Wagner; Binhua Ling; Sonya L Heath; Azizul Haque; Aimee McRae-Clark
Journal:  Curr HIV Res       Date:  2018       Impact factor: 1.581

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.